Venture Kick alumnus raises additional CHF 1.8 million
05.04.2018
Congratulations to Venture Kick alumnus Glycemicon, who have announced the final closing of the Series A round.
 Glycemicon Team
|
 |
Glycemicon AG, Swiss biotechnology company developing novel nutraceuticals for managing prediabetes, diabetes and obesity has reported the official closing of the Series A round. Together with the first closing of CHF 3.25 million announced last year, the last CHF 1.8 million investment round completes the total funding to CHF 5.05 million.
The company is using the funds to conduct its first clinical trial in humans with prediabetes and to conduct a further clinical study in cats with elevated blood sugar. Its first novel food product is based on the active compound THBA, a natural substance that modifies body fat tissue to help maintain normal blood glucose levels. THBA is naturally occurring in humans and pets and is also found in some natural food products.
About Glycemicon
Around half a million people in Switzerland alone suffer from diabetes. The costs for treating the various manifestations of the disease amount to approximately five percent of the total health care costs in this country. And diabetes is on the rise. Glycemicon is seeking to stop this development in its tracks with a substance that restores the impaired capacity of the fat cells in a diabetic patient’s body to respond to insulin.
The company is using the funds to conduct its first clinical trial in humans with prediabetes and to conduct a further clinical study in cats with elevated blood sugar. Its first novel food product is based on the active compound THBA, a natural substance that modifies body fat tissue to help maintain normal blood glucose levels. THBA is naturally occurring in humans and pets and is also found in some natural food products.
About Glycemicon
Around half a million people in Switzerland alone suffer from diabetes. The costs for treating the various manifestations of the disease amount to approximately five percent of the total health care costs in this country. And diabetes is on the rise. Glycemicon is seeking to stop this development in its tracks with a substance that restores the impaired capacity of the fat cells in a diabetic patient’s body to respond to insulin.